This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/kodPristupu/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F08%3A00007484%21RIV09-MSM-15110___/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F08%3A00007484%21RIV09-MSM-15110___
rdf:type
skos:Concept n17:Vysledek
rdfs:seeAlso
www.urol.cz
dcterms:description
Introduction: Prostate cancer is the most common tumor in the male population in Western Europe and USA. In the Czech Republic incidence is 96.87/100 000 inhabitants (NOR 2005). Prostate cancer is third most frequent causation of death for malignant tumor (28.52/1000 inhabitants). The main diagnostic marker for evidence of prostate cancer is prostate-specific antigen (PSA). In the blood portion of PSA is bound with proteins and the rest is free (free PSA). PSA Author email: is organ-specific but not cancer-specific, and serum levels may be elevated in the presence of benign prostatic hypertrophy, prostatitis and other non-malignant conditions. Low specificity of PSA is the reason for developing of new practices. The aim was to find out efficiency of free to total PSA ratio (fPSA/tPSA) pro diagnostic of the prostate cancer. Material and methods: Since 6/2006 to 2/2008 we provided 543 prostate biopsies on Department of Urology, Teaching Hospital Olomouc. We evaluated 418 cases with fre Introduction: Prostate cancer is the most common tumor in the male population in Western Europe and USA. In the Czech Republic incidence is 96.87/100 000 inhabitants (NOR 2005). Prostate cancer is third most frequent causation of death for malignant tumor (28.52/1000 inhabitants). The main diagnostic marker for evidence of prostate cancer is prostate-specific antigen (PSA). In the blood portion of PSA is bound with proteins and the rest is free (free PSA). PSA Author email: is organ-specific but not cancer-specific, and serum levels may be elevated in the presence of benign prostatic hypertrophy, prostatitis and other non-malignant conditions. Low specificity of PSA is the reason for developing of new practices. The aim was to find out efficiency of free to total PSA ratio (fPSA/tPSA) pro diagnostic of the prostate cancer. Material and methods: Since 6/2006 to 2/2008 we provided 543 prostate biopsies on Department of Urology, Teaching Hospital Olomouc. We evaluated 418 cases with fre Význam poměru volného PSA k celkovému PSA pro diagnostiku karcinomu prostaty
dcterms:title
Importance of fPSA/tPSA ratio for diagnostic of prostate cancer Význam poměru volného PSA k celkovému PSA pro diagnostiku karcinomu prostaty Importance of fPSA/tPSA ratio for diagnostic of prostate cancer
skos:prefLabel
Importance of fPSA/tPSA ratio for diagnostic of prostate cancer Importance of fPSA/tPSA ratio for diagnostic of prostate cancer Význam poměru volného PSA k celkovému PSA pro diagnostiku karcinomu prostaty
skos:notation
RIV/61989592:15110/08:00007484!RIV09-MSM-15110___
n3:aktivita
n18:S
n3:aktivity
S
n3:dodaniDat
n13:2009
n3:domaciTvurceVysledku
n6:6047998 n6:3804763
n3:druhVysledku
n8:A
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n5:predkladatel
n3:idSjednocenehoVysledku
371666
n3:idVysledku
RIV/61989592:15110/08:00007484
n3:jazykVysledku
n12:eng
n3:klicovaSlova
prostate carcinoma; PSA
n3:klicoveSlovo
n4:prostate%20carcinoma n4:PSA
n3:kodPristupu
n11:V
n3:kontrolniKodProRIV
[A74866F84F49]
n3:objednatelVyzkumneZpravy
Urologická klinika Olomouc
n3:obor
n10:FJ
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
4
n3:rokUplatneniVysledku
n13:2008
n3:tvurceVysledku
Vidlář, Aleš Študent, Vladimír Rosinska, Vlasta Hrabec, Martin
n16:organizacniJednotka
15110